Institutional Sign In

Go

Novartis Czech Republic - EBITDA Margin

Novartis Czech Republic`s EBITDA Margin reached 2.18 % in 2017. This is 17.9 % less than in the previous year.

$1.99

Buy EBITDA Margin data for Novartis Czech Republic.

$19.99

Buy all data for Novartis Czech Republic.

from $199/month

Buy annual subscriptions for all our products.

 
Company Unit 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
Amgen Czech Republic % ... ... ... ... ...             13.8 8.95 8.79 8.55 7.66    
Bayer Czech Republic % ... ... ...                 5.01 3.46 3.94 3.53 3.93    
GlaxoSmithKline Czech Republic % ... ... ...                 5.33 4.08 3.34 2.87 3.17    
Merck Czech Republic % ... ...                   4.14 4.77 2.85 2.98 5.18    
Novartis Czech Republic %                       1.56 1.78 1.77 2.41 2.42    
Pfizer Czech Republic % ... ...                   4.64 2.13 3.20 3.48 3.54    
Roche Czech Republic % ... ... ...                 4.14 4.20 6.66 6.07 3.84   ...
Sanofi-Aventis Czech Republic % ... ... ... ...               1.29 1.12 1.51 0.278 1.43    
Servier Czech Republic % ... ... ... ... ... ... ... ... ... ... ... ... 5.76 5.82 4.72 3.61    
Walmark % ... ... ...                 15.9 6.95 6.52 9.38 -19.6